The precision, or personalized, medicine movement predicts a future of patient care informed by measurable genetic, environmental, and behavioral characteristics unique to the individual patient.1 Implicit in this approach is the availability of biomarkers, including genetic variants, that accurately predict important health outcomes. Over the last decade, genome-wide association studies (GWAS) have identified hundreds of new genetic variations, largely single-nucleotide polymorphisms (SNPs) that might serve as biomarkers for many common conditions. In general, these account for little in the variance of disease, and the predictive value of such SNPs has been largely disappointing.2,3
Feero WG. Establishing the Clinical Validity of Arrhythmia-Related Genetic Variations Using the Electronic Medical Record: A Valid Take on Precision Medicine? JAMA. 2016;315(1):33–35. doi:10.1001/jama.2015.17702
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: